
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 28, 2012

OMEROS CORPORATION

(Exact name of registrant as specified in its charter)

Washington
(State or other jurisdiction
of incorporation)

001-34475
(Commission
File Number)

91-1663741
(IRS Employer
Identification No.)

**1420 Fifth Avenue, Suite 2600
Seattle, Washington 98101**
(Address of principal executive offices, including zip code)

(206) 676-5000
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 3.03 Material Modification to Rights of Security Holders.

On March 28, 2012, Omeros Corporation (“Omeros”) extended by one year the expiration dates of warrants to purchase up to an aggregate of 197,478 shares of Omeros Common Stock with an exercise price of \$12.25 per share (the “Warrants”). As a result of the extension, the expiration date of the Warrants has been changed to March 29, 2013 from March 29, 2012. The Warrants were originally issued by Omeros on March 29, 2007 to brokers who assisted Omeros in connection with its Series E Preferred Stock financing. Forms of the Warrants, as well as a related notice dated August 24, 2009 provided to holders of these Warrants, are filed as Exhibits 4.4, 4.5 and 4.6 to the Registration Statement on Form S-1/A filed by Omeros on September 16, 2009. A form of the notice confirming the one-year extension of the Warrants is included as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
4.1	Notice regarding the extension of the expiration date to March 29, 2013 of warrants to purchase up to an aggregate of 197,478 shares of the Common Stock of Omeros Corporation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OMEROS CORPORATION

By: /s/ Gregory A. Demopulos

Gregory A. Demopulos, M.D.

President, Chief Executive Officer, and Chairman of the
Board of
Directors

Date: March 29, 2012

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
---------------------------	--------------------

4.1	Notice regarding the extension of the expiration date to March 29, 2013 of warrants to purchase up to an aggregate of 197,478 shares of the Common Stock of Omeros Corporation.
-----	---

NOTICE OF WARRANT EXTENSION**March 28, 2012**

Reference is made to the Omeros Corporation Common Stock Purchase Warrant No. _____ (the “Warrant”) issued in the name of _____ (“Registered Holder”). The Warrant entitles Registered Holder to purchase up to _____ shares of Common Stock of Omeros Corporation (the “Company”) at a purchase price of \$12.25 per share.

Pursuant to Section 6 of the Warrant, the Warrant automatically terminates on March 29, 2012 (the “Expiration Date”). Notice is hereby given to the Registered Holder that the Board of Directors of the Company has extended the Expiration Date by one year to March 29, 2013.

Except for the extension of the Expiration Date described herein, the terms and conditions of the Warrant shall not be amended, waived or otherwise modified in any respect by this Notice.

OMEROS CORPORATION

By: _____
Gregory A. Demopulos, M.D.
Chairman & CEO